BerGenBio ASA
15
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
33.3%
5 terminated/withdrawn out of 15 trials
64.3%
-22.2% vs industry average
0%
0 trials in Phase 3/4
89%
8 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
Role: lead
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Role: lead
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Role: lead
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
Role: lead
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Role: collaborator
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Role: lead
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
Role: lead
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
Role: collaborator
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Role: collaborator
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
Role: collaborator
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
Role: lead
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Role: collaborator
A First-time-in-human Study of BGB149
Role: lead
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
Role: collaborator
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Role: lead
All 15 trials loaded